Immupharma (IMM)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

2.65p
   
  • Change Today:
    -0.015p
  • 52 Week High: 5.90
  • 52 Week Low: 1.09
  • Currency: UK Pounds
  • Shares Issued: 499.72m
  • Volume: 4,608,748
  • Market Cap: £13.24m
  • RiskGrade: 328
  • Beta: 0.14

Growth Ratings

EPS Growth shows the relative growth of a company's earnings over the last year.

The rise in total monies receivable for goods / services sold before expenses.

1yr EPS Growth Not Available
1yr Revenue Growth Not Available

Income Ratings

The percentage of the share price that a company pays out as dividends over a year.

The percentage change from the previous year in the dividend paid on each share.

Dividend Yield Not Available
1yr DPS Growth Not Available

Valuation Ratings

The share price as a ratio of revenue per share.

The share price as a ratio of net asset value.

Price Sales Ratio Not Available
Price Book Ratio
94.26% below the market average94.26% below the market average94.26% below the market average94.26% below the market average94.26% below the market average
86.05% below the sector average86.05% below the sector average86.05% below the sector average86.05% below the sector average86.05% below the sector average

Performance Ratings

In percentage total change in share price over 30 days.

In percentage total change in share price over 3 months.

Price Chg 30d
89.2% below the market average89.2% below the market average89.2% below the market average89.2% below the market average89.2% below the market average
75.51% below the sector average75.51% below the sector average75.51% below the sector average75.51% below the sector average75.51% below the sector average
Price Chg 3m
98.71% above the market average98.71% above the market average98.71% above the market average98.71% above the market average98.71% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

Technical Ratings

The Relative Strength Index measures a share price relative to itself and its recent history.

Momentum is an oscillator that measures the rate of price change.

RSI
35.38% below the market average35.38% below the market average35.38% below the market average35.38% below the market average35.38% below the market average
8.7% below the sector average8.7% below the sector average8.7% below the sector average8.7% below the sector average8.7% below the sector average
Momentum 20
5.08% below the market average5.08% below the market average5.08% below the market average5.08% below the market average5.08% below the market average
Sector averageSector averageSector averageSector averageSector average

Management Ratings

Operating Margin is profit as a percentage of sales.

Return on capital employed measures the return from invested and borrowed capital.

Operating Margin Not Available
ROCE Not Available

Profitability Ratings

Earnings per share, the company's profitability expressed on a per share basis.

Analysts' estimates of future EPS for the next 2 years.

EPS
48.82% below the market average48.82% below the market average48.82% below the market average48.82% below the market average48.82% below the market average
16.67% above the sector average16.67% above the sector average16.67% above the sector average16.67% above the sector average16.67% above the sector average
Forecast EPS Not Available

Profit/Loss Ratings

Monies produced from sales of goods and services after trade discounts, VAT, etc.

Operating Profit is the profit after deducting operating costs from gross profits.

Turnover Not Available
Operating Profit Loss
63.61% below the market average63.61% below the market average63.61% below the market average63.61% below the market average63.61% below the market average
12.50% above the sector average12.50% above the sector average12.50% above the sector average12.50% above the sector average12.50% above the sector average

Balance Sheet Ratings

The difference between current assets and current liabilities.

A current asset representing the company's financial liquidity.

Assets
81.04% below the market average81.04% below the market average81.04% below the market average81.04% below the market average81.04% below the market average
78.26% below the sector average78.26% below the sector average78.26% below the sector average78.26% below the sector average78.26% below the sector average
Cash
83.71% below the market average83.71% below the market average83.71% below the market average83.71% below the market average83.71% below the market average
82.98% below the sector average82.98% below the sector average82.98% below the sector average82.98% below the sector average82.98% below the sector average

Director Deal Ratings

The cumulative amount of stocks sold by company directors over 1 year

The cumulative amount of stocks bought by company directors over 1 year

Sells 1y Not Available
Buys 1y Not Available

Broker Ratings

The percentage of stockbrokers that rate the company as a Buy

The percentage of stockbrokers that rate the company as a Hold

Brokers Percent Buy Not Available
Brokers Percent Neutral Not Available

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Immupharma Market Data

Currency UK Pounds
Share Price 2.65p
Change Today -0.015p
% Change -0.56 %
52 Week High 5.90
52 Week Low 1.09
Volume 4,608,748
Shares Issued 499.72m
Market Cap £13.24m
Beta 0.14
RiskGrade 328

Immupharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
72.95% below the market average72.95% below the market average72.95% below the market average72.95% below the market average72.95% below the market average
45.83% below the sector average45.83% below the sector average45.83% below the sector average45.83% below the sector average45.83% below the sector average
Price Trend
80.88% above the market average80.88% above the market average80.88% above the market average80.88% above the market average80.88% above the market average
83.67% above the sector average83.67% above the sector average83.67% above the sector average83.67% above the sector average83.67% above the sector average
Income Not Available
Growth Not Available

Immupharma Dividends

No dividends found

Trades for 03-Apr-2025

Time Volume / Share Price
16:25 7,146 @ 2.80p
16:25 50,000 @ 2.57p
15:41 120,000 @ 2.63p
15:06 1,854 @ 2.70p
15:03 500 @ 2.62p

Immupharma Key Personnel

CEO Timothy Paul McCarthy

Top of Page